Management Team

With combined expertise in preclinical R&D, clinical trials, new drug registration, patent regulations and product/technology licensing, our team boasts a solid track record, having contributed to 8 successful NDAs. Our complementary expertise forms a strong foundation for comprehensive novel drug development.

Position Name Experience & Education
Director of R&D Chih-Peng Liu
Experience:
  1. Deputy Division Director, Targeted Drug & Delivery Technology Division, BDL, ITRI, Taiwan
  2. Manager, Preclinical Drug Discovery Technology Department, BDL, ITRI, Taiwan
  3. Principal Researcher, BDL, ITRI, Taiwan
  4. Project Director of Technology Development Program, ITRI, Taiwan
Education:
  1. MS & Ph.D. in Pharmacology, National Yang Ming University, Taiwan
  2. BS in Pharmacy, Taipei Medical College, Taiwan
Director of Food Ingredients & Additives Michael Lee
Experience:
  1. Senior Manager, San Fu Chemical Co., Taiwan.
  2. Manager, Tuntex Distinct Co., Taiwan.
  3. Engineer, ScinoPharm Taiwan, Taiwan.
Education:
  1. MS & BS in Chemical Engineering, Feng Chia University, Taiwan
Director of Project Management Wu-Chiang Chang
Experience:
  1. Director, Biomedical Ecosystem Development Office in Taiwan (BEST), MOST, Taiwan.
  2. BD Director, BELX Biopharmaceutical Co., Taiwan.
  3. Senior Manager, Strategic Planning Section, Biotechnology & Pharmaceutical Industries Promotion Office (BPIPO), MOEA, Taiwan
  4. Director, Cross-Strait Biotech Industry Cooperation Promotion Office, Development Center of Biotechnology (DCB), Taiwan.
  5. BD Manager, Commercialization and Industry Service Center, ITRI/ Assistant Manager, Biomedical Technology and Device Research Laboratories, ITRI, Taiwan.
  6. Administrator, BIO Office, Science and Technology Advisory Group (STAG), Executive Yuan, Taiwan.
Education:
  1. MBA, National Cheng Chi University, Taiwan.
  2. BS in Medical Technology, National Cheng Kung University, Taiwan.

Scientific Advisory Board (SAB) for New Drug Development.

A Scientific Advisory Board (SAB), including veteran executives specialized in drug discovery, CMC, toxicology, pharmacology, clinical, regulatory and marketing, was established. The board constantly contributes diverse, practical experience to strengthen SFB team's capabilities in screening in-licensing drug candidates, formulating drug development strategies and clinical and regulatory operations.

×

SFB101

First-in-Class novel drug in preclinical stage

What is a retinal disease?

The retina consists of millions of photoreceptor cells and other nerve cells responsible for receiving and organizing visual signals.1 Population-based studies show retinal diseases prevalence ranging from 5.35% to 21.02% in individuals aged 40 and above.2 Retinal diseases are the primary cause of irreversible blindness in developed countries and the second leading cause of blindness in developing countries, following cataracts.

Unmet Medical Needs

Anti-VEGF therapy reduces vision loss in wet macular degeneration and diabetic retinopathy. However, frequent intravitreal injections increase infection risk and burdens. Urgently needed are effective, patient-friendly drugs to prevent irreversible blindness.

Preclinical Stage

We are co-developing SFB101 with a national research institute in Taiwan, currently in the preclinical stage.

A novel drug candidate potential effective and patient-friendly treat the retinal diseases, preventing blindness.

  1. Richard H. Masland. Neuron. 2012; 76(2): 266-280.
  2. Matthew J Burton et al. Lancet Glob Health. 2021; 9(4): e489-e551.
×

SFB201

A First-in-class liposomal drug that effectively regulates the immune system's balance for prophylaxis against acute Graft-versus-Host Disease (aGvHD).

What is GvHD?

Many blood disorders, such as leukemia, require allogeneic hematopoietic stem cell transplantation (AHSCT) as a vital treatment option. However, graft-versus-host disease (GvHD), where immune cells from the donor attack the recipient's organs, remains a major and potentially fatal complication of AHSCT1.

The action of balancing the immune system.

SFB201 (originally named RGI-2001) is a new chemical entity (NCE) with liposomal formulation. The primary mechanism involves inducing an increase in regulatory T cells (Treg), initiating specific immune tolerance. These antigen-specific Tregs have been shown to downregulate the immune response directed toward specific antigens without causing generalized immunosuppression2.

Plan to enter Phase 3 clinical trial in 2024

The Phase 1/2a trial (NCT01379209)3 and the Phase 2b trial (NCT04014790)4in the USA has been completed. Planning to initiate a multi-center, multi-national Phase 3 clinical trial in the USA, Taiwan, and most likely, South Korea, in 2024.

SFB201 aims to enhance the success rate of AHSCT by preventing acute GvHD.

×

SFB202

×

SFB301